Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery

  • Ahn, Ki Jung (Department of Radiation Oncology, Inje University Busan Paik Hospital) ;
  • Park, Jisun (Department of Nuclear Medicine, Inje University Busan Paik Hospital) ;
  • Choi, Yunseon (Department of Radiation Oncology, Inje University Busan Paik Hospital)
  • Received : 2017.08.17
  • Accepted : 2017.10.10
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to evaluate the prognostic effects of lymphovascular invasion (LVI) in triple-negative breast cancer (TNBC) patients who underwent surgical resection. Materials and Methods: A total of 63 non-metastatic TNBC patients who underwent surgical resection were retrospectively investigated from 2007 to 2016 in Inje University Busan Paik Hospital. Pathological tests revealed that 12 patients (19.0%) had LVI. Approximately 61.9% (n = 39) of the patients' samples stained positive for p53. Additional chemotherapy and radiotherapy (RT) were performed in 53 (84.1%) and 47 (74.6%) patients, respectively. Results: The median follow-up period was 39.5 months (range, 5.9 to 123.0 months). The pathological T stage (p = 0.008), N stage (p = 0.014), and p53 positivity (p = 0.044) were associated with LVI. Overall, the 3-year disease-free survival (DFS) rate and overall survival (OS) rate were 85.4% and 90.2%, respectively. Ten patients (15.9%) experienced relapse. LVI (n = 12) was associated with relapses (p = 0.016). p53 positivity was correlated with poor DFS (p = 0.048). Furthermore, LVI was related to poor DFS (p = 0.011) and OS (p = 0.001) and considered as an independent prognostic factor for DFS (p = 0.039). The 3-year DFS of patients with LVI (n = 12) was only 58.3%. Adjuvant RT minimized the negative prognostic effect of LVI on DFS (p = 0.068 [with RT] vs. p = 0.011 [without RT]). Conclusion: LVI was related to the detrimental effects of disease progression and survival of TNBC patients. Thus, a more effective treatment strategy is needed for TNBC patients with LVI.

Keywords

References

  1. Rakha EA, Martin S, Lee AH, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 2012;118:3670-80. https://doi.org/10.1002/cncr.26711
  2. Liu YL, Saraf A, Lee SM, et al. Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 2016;157:555-64. https://doi.org/10.1007/s10549-016-3837-5
  3. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-12. https://doi.org/10.1097/01.sla.0000133355.48672.22
  4. Krishnamurti U, Wetherilt CS, Yang J, Peng L, Li X. Tumorinfiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triplenegative but not estrogen receptor-positive breast cancers. Hum Pathol 2017;64:7-12. https://doi.org/10.1016/j.humpath.2017.01.004
  5. Lee HJ, Park IA, Song IH, et al. Tertiary lymphoid structures: prognostic significance and relationship with tumourinfiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol 2016;69:422-30. https://doi.org/10.1136/jclinpath-2015-203089
  6. Shen S, Sun Q, Liang Z, et al. A prognostic model of triplenegative breast cancer based on miR-27b-3p and node status. PLoS One 2014;9:e100664. https://doi.org/10.1371/journal.pone.0100664
  7. Budakoglu B, Altundag K, Aksoy S, et al. Outcome of 561 nonmetastatic triple negative breast cancer patients: multi-center experience from Turkey. J BUON 2014;19:872-8.
  8. Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res 2015;5:2929-43.
  9. Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med 2015;12:106-16.
  10. Gujam FJ, Going JJ, Mohammed ZM, Orange C, Edwards J, McMillan DC. Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer 2014;14:676. https://doi.org/10.1186/1471-2407-14-676
  11. Kim HA, Seong MK, Kim EK, et al. Evaluation of the survival benefit of different chemotherapy regimens in patients with T1-2N0 triple-negative breast cancer. J Breast Cancer 2015;18:271-8. https://doi.org/10.4048/jbc.2015.18.3.271
  12. Pistelli M, Pagliacci A, Battelli N, et al. Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. Anticancer Res 2013;33:2737-42.
  13. Agarwal G, Nanda G, Lal P, et al. Outcomes of triple-negative breast cancers (TNBC) compared with non-TNBC: does the survival vary for all stages? World J Surg 2016;40:1362-72. https://doi.org/10.1007/s00268-016-3422-4
  14. Mohammed ZM, McMillan DC, Edwards J, et al. The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol 2013;13:31. https://doi.org/10.1186/1472-6890-13-31
  15. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-8. https://doi.org/10.1200/JCO.2010.33.4714
  16. Orecchia R. Tailoring radiotherapy according to cancer subtypes. Breast 2017;34 Suppl 1:S91-S94. https://doi.org/10.1016/j.breast.2017.06.036
  17. Truong PT, Lesperance M, Culhaci A, Kader HA, Speers CH, Olivotto IA. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int J Radiat Oncol Biol Phys 2005;62:175-82. https://doi.org/10.1016/j.ijrobp.2004.09.013
  18. Truong PT, Olivotto IA, Speers CH, Wai ES, Berthelet E, Kader HA. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys 2004;58:797-804. https://doi.org/10.1016/S0360-3016(03)01626-2
  19. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. https://doi.org/10.1002/cncr.22381
  20. Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:217-24. https://doi.org/10.1093/jjco/hyp007
  21. Lehmann-Che J, Andre F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010;15:246-52. https://doi.org/10.1634/theoncologist.2009-0243
  22. Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. https://doi.org/10.1080/15384047.2017.1323582
  23. Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov 2014;4:405-14. https://doi.org/10.1158/2159-8290.CD-13-0136
  24. Sa-Nguanraksa D, Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P. High vascular endothelial growth factor gene expression predicts poor outcome in patients with nonluminal A breast cancer. Mol Clin Oncol 2015;3:1103-8. https://doi.org/10.3892/mco.2015.574
  25. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumabcontaining therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42. https://doi.org/10.1016/S1470-2045(13)70335-8
  26. Ma X, Wang X, Huang J, et al. Bevacizumab addition in neoadjuvant treatment increases the pathological complete response rates in patients with HER-2 negative breast cancer especially triple negative breast cancer: a meta-analysis. PLoS One 2016;11:e0160148. https://doi.org/10.1371/journal.pone.0160148
  27. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010;28:3239-47. https://doi.org/10.1200/JCO.2008.21.6457
  28. Klahan S, Wong HS, Tu SH, et al. Identification of genes and pathways related to lymphovascular invasion in breast cancer patients: a bioinformatics analysis of gene expression profiles. Tumour Biol 2017 Jun 27 [Epub]. http://doi.org/10.1177/1010428317705573.

Cited by

  1. Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23 vol.50, pp.4, 2018, https://doi.org/10.4143/crt.2017.575
  2. Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multi vol.51, pp.3, 2017, https://doi.org/10.4143/crt.2018.424
  3. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast‐enhanced‐MRI‐based radiomics vol.50, pp.3, 2017, https://doi.org/10.1002/jmri.26688
  4. A study of CD10 positivity of stromal cells in core needle biopsy specimen of breast cancer patients and its relation with histological grade and lymphovascular invasion vol.64, pp.3, 2017, https://doi.org/10.4103/ijpm.ijpm_601_20
  5. Relationship between lymphovascular invasion and molecular subtypes in invasive breast cancer vol.75, pp.4, 2017, https://doi.org/10.1111/ijcp.13897
  6. Lymphovascular Invasion as a Predictive Factor for Recurrence in Triple-Negative Breast Cancer vol.83, pp.suppl2, 2021, https://doi.org/10.1007/s12262-021-02783-5
  7. A retrospective review of MRI features associated with metastasis-free survival in women with breast cancer: focusing on skin thickening and skin enhancement vol.94, pp.1128, 2021, https://doi.org/10.1259/bjr.20210472